Beactica closes financing round to accelerate its pipeline of novel cancer therapeutics
Uppsala, Sweden – 28 August 2018Beactica , the Swedish drug discovery company, today announced the completion of its latest financing round, providing significant funds that will be used to advance the Company’s internal pipeline of discovery-stage oncology programmes. The financing round was Beactica’s most successful to date, being almost 60% oversubscribed. Over one third of the investors were new to Beactica, raising the majority of the funds. The remainder was provided by several existing shareholders, including ALMI Invest and UNIONEN. The funds raised will